Replies to post #27776 on Marker Therapeutics Inc (MRKR)

[poods]

Read this if you want to appreciate just how rare a CR is with Folfirinox. We have one CR with the first 5 evaluable patients in arm A treated with Folfirinox and one more SD in the evaluable 5 treated that has yet to progress.
This very unexpected finding plus the antigen/epitope spreading strongly points to Multi-TAA synergism with chemotherapy. This is akin to the synergism seen between chemo and pembro in lung cancer. We don't have 100% certainty yet, as if we did this would today be a multibillion dollar company. However, we're coming close to that and the market continues to to yawn. It will wake up soon. One more CR in Group A in the remaining patients dosed who have not progressed or waiting to be dosed and we reach certainty IMO. That's your near term catalyst and it could come any time. The CR in the article took a couple of years but ours took only a few months with cells.
http://www.alliedacademies.org/articles/a-3year-disease-free-survival-in-a-patient-with-metastatic-pancreatic-adenocarcinoma-following-folfirinox-chemotherapy-a-case-repo-10396.html

[ImmunoVest]

Radiation therapy may also poke holes. Maybe MTAA could work with radiation to
increase the abscopal effect. This would be less toxic than chemo as you
may need to only initiate the attack and not a full killing fraction schedule.
Moreover, more targeted proton or carbon ion may be better and less damaging to immune system.